title: Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.
abstract: OBJECTIVE
  To compare the risk of acute myocardial infarction, heart failure, and death in patients with type 2 diabetes treated with rosiglitazone and pioglitazone.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  Ontario, Canada.
  
  
  METHODS
  Outpatients aged 66 years and older who were started on rosiglitazone or pioglitazone between 1 April 2002 and 31 March 2008.
  
  
  METHODS
  Composite of death or hospital admission for either acute myocardial infarction or heart failure. In a secondary analysis, each outcome was also examined individually.
  
  
  RESULTS
  39 736 patients who started on either pioglitazone or rosiglitazone were identified. During the six year study period, the composite outcome was reached in 895 (5.3%) of patients taking pioglitazone and 1563 (6.9%) of patients taking rosiglitazone. After extensive adjustment for demographic and clinical factors and drug doses, pioglitazone treated patients had a lower risk of developing the primary outcome than did patients treated with rosiglitazone (adjusted hazard ratio 0.83, 95% confidence interval 0.76 to 0.90). Secondary analyses revealed a lower risk of death (adjusted hazard ratio 0.86, 0.75 to 0.98) and heart failure (0.77, 0.69 to 0.87) with pioglitazone but no significant difference in the risk of acute myocardial infarction (0.95, 0.81 to 1.11). One additional composite outcome would be predicted to occur annually for every 93 patients treated with rosiglitazone rather than pioglitazone.
  
  
  CONCLUSIONS
  Among older patients with diabetes, pioglitazone is associated with a significantly lower risk of heart failure and death than is rosiglitazone. Given that rosiglitazone lacks a distinct clinical advantage over pioglitazone, continued use of rosiglitazone may not be justified.
authors.affiliation: Division of Clinical Pharmacology and Toxicology, Department of Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. dnj@ices.on.ca
authors.forename: David N
authors.initials: DN
authors.lastname: Juurlink
authors.forename: Tara
authors.initials: T
authors.lastname: Gomes
authors.forename: Lorraine L
authors.initials: LL
authors.lastname: Lipscombe
authors.forename: Peter C
authors.initials: PC
authors.lastname: Austin
authors.forename: Janet E
authors.initials: JE
authors.lastname: Hux
authors.forename: Muhammad M
authors.initials: MM
authors.lastname: Mamdani
mesh_terms: D000368:Aged; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D009203:Myocardial Infarction / Q000139:chemically induced*; D000077205:Pioglitazone; D012189:Retrospective Studies; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone
references.citation: Diabetes Care. 2004 May;27(5):1047-53
references.pmid: 15111519
references.citation: Int J Cardiol. 2009 Jan 24;131(3):298-304
references.pmid: 18684530
references.citation: Diabet Med. 2005 Aug;22(8):986-93
references.pmid: 16026362
references.citation: JAMA. 2007 Dec 12;298(22):2634-43
references.pmid: 18073359
references.citation: Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):753-9
references.pmid: 18613215
references.citation: Arch Intern Med. 2003 Feb 24;163(4):481-6
references.pmid: 12588209
references.citation: Mayo Clin Proc. 2004 Apr;79(4):571; author reply 575-7
references.pmid: 15065625
references.citation: J Pharmacol Exp Ther. 1998 Feb;284(2):751-9
references.pmid: 9454824
references.citation: N Engl J Med. 2007 Jul 5;357(1):67-9
references.pmid: 17551162
references.citation: Clin Cardiol. 2008 Sep;31(9):397-403
references.pmid: 18781598
references.citation: Diabetes Care. 2005 Jul;28(7):1547-54
references.pmid: 15983299
references.citation: J Clin Epidemiol. 2010 Jan;63(1):2-6
references.pmid: 19230611
references.citation: N Engl J Med. 2004 Aug 5;351(6):543-51
references.pmid: 15295047
references.citation: J Am Coll Cardiol. 2005 Jun 21;45(12):1925-31
references.pmid: 15963388
references.citation: Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1065-71
references.pmid: 17674425
references.citation: N Engl J Med. 2007 Aug 30;357(9):844-6
references.pmid: 17687124
references.citation: Diabetes Care. 1999 Apr;22(4):562-8
references.pmid: 10189532
references.citation: Am Heart J. 2002 Aug;144(2):290-6
references.pmid: 12177647
references.citation: N Engl J Med. 2007 Jul 5;357(1):28-38
references.pmid: 17551159
references.citation: Lancet. 2005 Oct 8;366(9493):1279-89
references.pmid: 16214598
references.citation: JAMA. 2007 Sep 12;298(10):1189-95
references.pmid: 17848653
references.citation: Nat Med. 2005 Aug;11(8):861-6
references.pmid: 16007095
references.citation: Lancet. 2007 Sep 29;370(9593):1129-36
references.pmid: 17905165
references.citation: Clin Ther. 2002 Mar;24(3):378-96
references.pmid: 11952022
references.citation: JAMA. 2007 Sep 12;298(10):1216-8
references.pmid: 17848659
references.citation: BMJ. 2005 Apr 23;330(7497):960-2
references.pmid: 15845982
references.citation: N Engl J Med. 2007 Jun 14;356(24):2457-71
references.pmid: 17517853
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9406-11
references.pmid: 15956187
references.citation: Mayo Clin Proc. 2003 Sep;78(9):1088-91
references.pmid: 12962163
references.citation: N Engl J Med. 2007 Aug 30;357(9):938-9; author reply 939-40
references.pmid: 17806135
references.citation: Med Care. 2005 Feb;43(2):182-8
references.pmid: 15655432
references.citation: JAMA. 2007 Sep 12;298(10):1180-8
references.pmid: 17848652
references.citation: Diabet Med. 2008 Jul;25(7):871-4
references.pmid: 18644075
references.citation: Diabetes Care. 2002 Mar;25(3):512-6
references.pmid: 11874939
references.citation: N Engl J Med. 2006 Mar 30;354(13):1352-61
references.pmid: 16510739